FR2925491B1 - Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules - Google Patents

Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Info

Publication number
FR2925491B1
FR2925491B1 FR0708861A FR0708861A FR2925491B1 FR 2925491 B1 FR2925491 B1 FR 2925491B1 FR 0708861 A FR0708861 A FR 0708861A FR 0708861 A FR0708861 A FR 0708861A FR 2925491 B1 FR2925491 B1 FR 2925491B1
Authority
FR
France
Prior art keywords
cells
transport
active agents
cationic lipids
new classes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0708861A
Other languages
English (en)
French (fr)
Other versions
FR2925491A1 (fr
Inventor
Olivier Zelphati
Stephane Moutard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OZ BIOSCIENCES Sas
Original Assignee
OZ BIOSCIENCES Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OZ BIOSCIENCES Sas filed Critical OZ BIOSCIENCES Sas
Priority to FR0708861A priority Critical patent/FR2925491B1/fr
Priority to PCT/FR2008/001755 priority patent/WO2009106713A2/fr
Priority to JP2010538832A priority patent/JP2011509074A/ja
Priority to EP08872753.2A priority patent/EP2285772B1/fr
Priority to CA2708988A priority patent/CA2708988C/fr
Publication of FR2925491A1 publication Critical patent/FR2925491A1/fr
Application granted granted Critical
Publication of FR2925491B1 publication Critical patent/FR2925491B1/fr
Priority to US13/028,940 priority patent/US9107931B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR0708861A 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules Active FR2925491B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0708861A FR2925491B1 (fr) 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
PCT/FR2008/001755 WO2009106713A2 (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
JP2010538832A JP2011509074A (ja) 2007-12-19 2008-12-16 活性剤を細胞内に輸送するためのカチオン性脂質の新規なクラス
EP08872753.2A EP2285772B1 (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
CA2708988A CA2708988C (fr) 2007-12-19 2008-12-16 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
US13/028,940 US9107931B2 (en) 2007-12-19 2011-02-16 Class of cationic lipids for transporting active agents into cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0708861A FR2925491B1 (fr) 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Publications (2)

Publication Number Publication Date
FR2925491A1 FR2925491A1 (fr) 2009-06-26
FR2925491B1 true FR2925491B1 (fr) 2010-09-03

Family

ID=39731919

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0708861A Active FR2925491B1 (fr) 2007-12-19 2007-12-19 Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules

Country Status (6)

Country Link
US (1) US9107931B2 (enExample)
EP (1) EP2285772B1 (enExample)
JP (1) JP2011509074A (enExample)
CA (1) CA2708988C (enExample)
FR (1) FR2925491B1 (enExample)
WO (1) WO2009106713A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766482B1 (en) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Micrornas in neurodegenerative disorders
CA2868463C (en) 2012-03-28 2021-01-19 University Of Central Florida Research Foundation, Inc. Polyamine transport selective therapeutic agents with enhanced stability
WO2013148219A1 (en) 2012-03-28 2013-10-03 University Of Central Florida Research Foundation, Inc. Anti-metatstatic agents predicated upon polyamine-macrocyclic conjugates
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US9439433B2 (en) 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
US8853278B1 (en) 2013-05-22 2014-10-07 Curza Global, Llc Compositions comprising a biocidal polyamine
US20160110406A1 (en) * 2014-10-16 2016-04-21 Microsoft Technology Licensing, Llc Validation of data across multiple data stores
EP3542825A1 (en) 2014-11-10 2019-09-25 Ethris GmbH Induction of osteogenesis by delivering bmp encoding rna
US10385030B2 (en) * 2015-01-30 2019-08-20 Nof Corporation Cationic lipid
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
JP7041673B2 (ja) * 2016-10-13 2022-03-24 カーノット， エルエルシー Ｎ－アシルエタノールアミド誘導体およびその使用
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
AU2018249550B2 (en) 2017-04-05 2023-11-30 Curza, Inc. Compositions and methods comprising a triaryl polyamine
BR112021014528A2 (pt) 2019-02-14 2021-10-13 Ethris Gmbh Composição farmacêutica, e, método para analisar o efeito de um polirribonucleotídeo na ciliogênese
WO2022096582A1 (en) 2020-11-04 2022-05-12 Ethris Gmbh Use of ifn-lambda mrna for treating viral infections
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency
EP4480943A1 (en) 2023-06-22 2024-12-25 Oz Biosciences New class of lipids for delivering active ingredients into cells
IT202300015291A1 (it) 2023-07-20 2025-01-20 Fond Riccardo Terzi E Silvio Albini Sistema di rilascio comprendente nanoparticelle lipidiche o polimeriche comprendenti ormoni tiroidei
WO2025097659A1 (en) * 2023-11-08 2025-05-15 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
CN121241044A (zh) * 2024-04-01 2025-12-30 深圳厚存纳米药业有限公司 脂质和脂质纳米颗粒制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1351368A (fr) * 1960-12-05 1964-02-07 Merck & Co Inc Composés d'isocyanates organiques et leur procédé de fabrication
CH448122A (de) * 1963-10-14 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung von Estern
JPS6039716B2 (ja) * 1982-02-02 1985-09-07 ライオン株式会社 カチオン性界面活性剤組成物
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
US4917826A (en) * 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
EP0320976A1 (en) * 1987-12-18 1989-06-21 Ajinomoto Co., Inc. Arginine derivatives and cosmetic compositions comprising the same
AU666416B2 (en) * 1993-01-29 1996-02-08 Tanabe Seiyaku Co., Ltd. Ellipticine derivative and process for preparing the same
GB9326518D0 (en) * 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
JPH08239398A (ja) * 1995-03-03 1996-09-17 Sogo Yatsukou Kk 水不溶性、自己支持性透明ｄｎａ・脂質複合体フィルムおよびその製造方法
EP0775751A3 (en) * 1995-11-22 1998-06-10 F. Hoffmann-La Roche Ag Cell transfection
ATE244021T1 (de) * 1996-01-17 2003-07-15 Hoffmann La Roche Transfektionskompetente moleküle
EP0784984B1 (en) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Transfection competent molecules
EP1046394A3 (en) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
CN1452617A (zh) * 2000-09-05 2003-10-29 甘瑟尔股份有限公司 酸敏感化合物、其制备方法和用途
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
US20050043534A1 (en) * 2001-07-11 2005-02-24 Alicja Bielawska Modulators of ceramidase and methods of used based thereon
AU2002368202B2 (en) * 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
AU2003217028A1 (en) * 2002-03-27 2003-10-13 Cambridge University Technical Services Ltd Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
US7838685B2 (en) * 2005-04-27 2010-11-23 Shinji Takeoka Cationic amino acid type lipid
NZ569535A (en) * 2005-12-30 2011-12-22 Revance Therapeutics Inc Arginine heteromers for topical administration

Also Published As

Publication number Publication date
US9107931B2 (en) 2015-08-18
JP2011509074A (ja) 2011-03-24
EP2285772A2 (fr) 2011-02-23
CA2708988C (fr) 2017-03-28
WO2009106713A3 (fr) 2009-11-26
WO2009106713A2 (fr) 2009-09-03
FR2925491A1 (fr) 2009-06-26
CA2708988A1 (fr) 2009-09-03
EP2285772B1 (fr) 2022-07-13
US20120015865A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
EP1992027A4 (en) CATALOG MATERIAL FOR LI-ION BATTERY APPLICATIONS
EP2160787A4 (en) WATER-FREE ELECTROLYTE SOLUTION FOR A LITHIUMION SECONDARY BATTERY AND LITHIUM ION SECONDARY BATTERY THEREWITH
FR20C1066I1 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
EP1996701A4 (en) CYTOTOXICITY PROCESSING IN SURFACE EXPRESSION OF TROP-2 SHOWING CELLS
EP2413403A4 (en) NEGATIVE ELECTRODE MATERIAL FOR A SECONDARY BATTERY WITH NON-ACID ELECTROLYTE AND SECONDARY BATTERY WITH NON-ACID ELECTROLYTE AND THIS MATERIAL
EP2413404A4 (en) NEGATIVE ELECTRODE MATERIAL FOR A SECONDARY BATTERY WITH NON-ACID ELECTROLYTE AND SECONDARY BATTERY WITH NON-ACID ELECTROLYTE AND THIS MATERIAL
EP2701753A4 (en) CELL-FRIENDLY INVERSE AND OPAQUE HYDROGELS FOR CELLULAR SEPARATION, DRUG AND PROTEIN DELIVERY, AND FUNCTIONAL NANOPARTICLE SEPARATION
EP2352192A4 (en) NEGATIVE ELECTRODE MATERIAL FOR A NON-WATER SECONDARY BATTERY
EP2147121A4 (en) SYNTHETIC EXPRESSION VECTORS FOR INSECT CELLS
EP2500966A4 (en) NEGATIVELY ACTIVE MATERIAL FOR A LITHIUM SUBSTANCE BATTERY AND LITHIUM SUBSTITUTING BATTERY THEREWITH
EP1888123A4 (en) CELL THERAPY FOR EYE GENERATION
EP2435206A4 (en) ELECTRODE SURFACE MATERIALS AND PLASMA CHEMICAL STRUCTURES
EP2138481A4 (en) WATER-FREE ELECTROLYTE SOLUTION FOR LITHIUM CERTAIN BATTERY AND LITHIUM CYCLE BATTERY THEREWITH
FR2880198B1 (fr) Electrode nanostructuree pour microbatterie
EP2330664A4 (en) POSITIVE ELECTRODE MATERIAL FOR LITHIUM SECONDARY BATTERIES
EP2436069A4 (en) NETWORKED HIGH NANOSTRUCTURES USING HIGH CAPACITY TOOLS FOR USE IN RECHARGEABLE BATTERIES
EP1807506A4 (en) MIRKOVER CAPSULATION OF CELLS IN HYDROGELS BY ELECTROSTATIC POTENTIALS
BRPI0815142A2 (pt) Forma cristalina do sal de dicloridrato ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)-3-met ilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)- 1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metelpropi l)carbamato de metila
EP1979979A4 (en) ADDITIVES FOR A WATER-FREE ELECTROLYTE AND LITHIUM SECONDARY BATTERY THEREWITH
EP1723686A4 (en) THERMAL MANAGEMENT SYSTEMS FOR BATTERY PACKS
EP2393420A4 (en) LOADING-CONSISTENT CONTRACTS
EP2037515A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL FOR A RECHARGEABLE LITHIUMION BATTERY AND NEGATIVE ELECTRODE
EP1952224A4 (en) APPLICATION FOR ACTIVE NOTES
EP2206182A4 (en) ACTIVE CATHODE MATERIAL FOR LITHIUM SECONDARY BATTERY
EP1989232A4 (en) CYTOTOXICITY COMMUNICATION OF CELLS THAT SHOW SURFACE EXPRESSION OF CD59

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18